Hosted on MSN39m
Regeneron Culls Losses After High-Dose Eylea Sales Disappoint
Regeneron stock fell slightly Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.
Pegasystems Inc. (PEGA): RBC Upgrade Highlights Growth Potential Amid Launch of Next-Gen AI-Powered Smart Dispute Solution
We recently compiled a list of the Top 10 Unlikely AI Stocks with Tremendous Upside Potential. In this article, we are going ...
BioPharma Dive49m
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...